COVID‐19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action

Conforti, Claudio; Giuffrida, Roberta; Dianzani, Caterina; Meo, Nicola di; Zalaudek, Iris

doi:10.1111/dth.13298

Cited by 85 publications

(98 citation statements)

References 5 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…50 Hubungan infeksi SARS-CoV-2 dengan hipersensitivitas dan penyakit autoimun juga belum dilaporkan. 51 Belum ada studi yang menghubungkan riwayat penyakit asma dengan kemungkinan terinfeksi SARS-CoV-2. Namun, studi meta-analisis yang dilakukan oleh Yang, dkk.…”

Section: Faktor Risikounclassified

Coronavirus Disease 2019: Tinjauan Literatur Terkini

Susilo¹,

Rumende²,

Pitoyo³

et al. 2020

JPDI

732

251

View full text Add to dashboard Cite

Pada awal 2020, dunia dikejutkan dengan mewabahnya pneumonia baru yang bermula dari Wuhan, Provinsi Hubei yang kemudian menyebar dengan cepat ke lebih dari 190 negara dan teritori. Wabah ini diberi nama coronavirus disease 2019 (COVID-19) yang disebabkan oleh Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Penyebaran penyakit ini telah memberikan dampak luas secara sosial dan ekonomi. Masih banyak kontroversi seputar penyakit ini, termasuk dalam aspek penegakkan diagnosis, tata laksana, hingga pencegahan. Oleh karena itu, kami melakukan telaah terhadap studi-studi terkait COVID-19 yang telah banyak dipublikasikan sejak awal 2020 lalu sampai dengan akhir Maret 2020.

show abstract

Section: Faktor Risikounclassified

Coronavirus Disease 2019: Tinjauan Literatur Terkini

Susilo¹,

Rumende²,

Pitoyo³

et al. 2020

JPDI

732

251

View full text Add to dashboard Cite

show abstract

“…A call for action." 1 In their letter, the authors wonder whether this is the most appropriate time to start immunosuppressive therapy with conventional or biological antipsoriatic treatments, such as cyclosporine (CsA), methotrexate and tumor necrosis factor (TNF)-alpha blockers.…”

Section: Dear Editormentioning

confidence: 99%

Antipsoriatic treatments during COVID ‐19 outbreak

Lernia

2020

Dermatologic Therapy

View full text Add to dashboard Cite

“…Some authors have proposed a classification of immunomodulators and immunosuppressants according to "likely risk", suggesting continuation of TNFα inhibitors and anti-IL biologics ("likely moderate risk") in the presence of mild viral symptoms [26]. Other authors recommend a limitation or avoidance of ciclosporin, methotrexate, and TNFα inhibitors for dermatologic patients in areas with high infection rates and stopping all immunosuppressive and biological therapy when exposure to confirmed COVID-19 cases occurs [27]. Finally, some authors propose that the use of biologic therapies that modulate T helper (Th)-1 responses, such as TNFα inhibitors abatacept and ustekinumab, might specifically require more stringent precautions [28].…”

mentioning

confidence: 99%